A number of innovations in the treatment of advanced non-Hodgkin's lymphoma have emerged in the last 20 years, one of which is the use of combination protocols formerly reserved for the treatment of patients with Hodgkin's disease. These regimens, employing a wide variety of antineoplastic agents in combination, show promise for improving survival rates for varying lenghts of time. Other approaches - such as intensification of therapy; the addition of mitoxantrone to the oncologist's armamentarium; high-dose therapy with transplantation; and the use of hematopoietic growth factors, biologic response modifiers, and monoclonal antibodies - hold much promise for further advances.
|Original language||English (US)|
|Number of pages||7|
|State||Published - 1991|
ASJC Scopus subject areas
- Pharmaceutical Science